Markets & Finance

Thomas Weisel Keeps Outperform on Santarus

Thomas Weisel keeps the outperform rating on Santarus (SNTS).

Analyst Donald Ellis says Santarus expects to launch its new Rapinex product in the fourth quarter, ahead of his first-half 2005 estimate. He notes the 230-member salesforce will detail Rapinex to high-prescribing physicians in treating gastrointestinal disorders. He expects FDA approval of 40 mg Rapinex powder-for-suspension by year end.

Ellis says the company's immediate-release, proton pump inhibitor technology provides a more rapid onset of action than the ones currently on the market. He maintains the 48 cents second-quarter loss, and the $2.48 2004 loss estimates until he has a better grasp on launch quantities.

Best LBO Ever

Sponsored Financial Commentaries

Sponsored Links

Buy a link now!

blog comments powered by Disqus